Intestinal Fucosylation: A Key Regulatory Hub in Homeostasis and Disease Pathogenesis
Open Access
- 24 August 2026
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1226
Abstract
Inflammatory bowel disease (IBD) and colorectal cancer (CRC) are heterogeneous intestinal disorders that pose significant threats to human health and share common pathological features, including intestinal mucosal barrier disruption and gut microbiota dysbiosis, in which fucosylation acts as a critical regulatory mediator. Fucosylation is a highly conserved post-translational glycosylation modification involving the enzymatic transfer of fucose residues to glycoproteins and glycolipids. This tightly regulated process plays essential roles in maintaining intestinal homeostasis, mediating host–microbiota interactions and regulating immune responses. This review adopts a physiology-to-pathology framework, delineating fucosylation’s operational principles in healthy intestines and its dysregulation in IBD and CRC. It summarizes the spatial distribution of fucosylation, its regulatory mechanisms, and its roles in disease pathogenesis, and also discusses its potential as a diagnostic biomarker and therapeutic target. Finally, this review highlights future research directions to bridge mechanistic insights with clinical translation, emphasizing the promise of fucosylation in the precision diagnosis and treatment of intestinal disorders.Keywords
Funding Information
- Natural Science Foundation of Henan Province (262300420201)
- Startup Foundation for Doctor of Henan Medical University (XYBSKYZZ300-505393)
This publication has 179 references indexed in Scilit:
- POFUT1 as a cancer biomarker: insights into its oncogenic mechanisms and clinical relevanceJournal of Molecular Medicine, 2025
- 2′‐Fucosyllactose Modulates the Intestinal Immune Response to Gut Microbiota and Buffers Experimental Colitis in Mice: An Integrating Investigation of Colonic Proteomics and Gut Microbiota AnalysisFood Science & Nutrition, 2025
- Altered glycosylation in cancer: molecular functions and therapeutic potentialCancer Communications, 2024
- Altered expression of Sialyl Lewis X in experimental models of Parkinson’s diseaseJournal of Molecular Medicine, 2024
- Insight on molecular pathogenesis and pharmacochaperoning potential in phosphomannomutase 2 deficiency, provided by novel human phosphomannomutase 2 structuresJournal of Inherited Metabolic Disease, 2021
- Chemo‐Enzymatic Synthesis of S. mansoni O‐Glycans and Their Evaluation as Ligands for C‐Type Lectin Receptors MGL, DC‐SIGN, and DC‐SIGNRChemistry – A European Journal, 2020
- The Effects of PMM2-CDG-Causing Mutations on the Folding, Activity, and Stability of the PMM2 ProteinHuman Mutation, 2015
- Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancerCancer, 2011
- Increased tumorigenicity of rat colon carcinoma cells after ?1,2-fucosyltransferaseFTA anti-sense cDNA transfectionInternational Journal of Cancer, 1999
- Glycoprotein containing vesicles in the surface epithelial cells of the ascending colon of the ratThe Anatomical Record, 1977